From: Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease
Variable | Start | Stop | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Group (treatment) | Yes (n) | No (n) | Comparison to A (placebo 4wks); P | Odds ratio/Kappa coefficient (95% CI) | Group (treatment) | Yes (n) | No (n) | Comparison to E (HCQ 4wks); P | Odds ratio/ Kappa coefficient (95% CI) | |
Responders to treatment (defined per protocol) | A (placebo 4wks) | 0 | 13 | E (HCQ 12wks) | 0 | 3 | ||||
B (HCQ 4wks) | 0 | 7 | 1.000a | Not applc | F (placebo 12wks) | 0 | 5 | 1.000a | Not applc | |
C (HCQ 4wks) | 3 | 9 | Not applb,c | Not applc | G (no med. 12wks) | 1 | 2 | Not applb,c | Not applc | |
B + C (combined) | 3 | 16 | 0.253a | Not applc | F + G combined | 1 | 7 | 1.000a | Not applc | |
Responders to treatment (defined by MID) | A (placebo 4wks) | 2 | 11 | E (HCQ 12wks) | 0 | 3 | ||||
B (HCQ 4wks) | 1 | 5 | 1.000a | 1.100 (0.079–15.16) | F (placebo 12wks) | 3 | 2 | 0.196a | Not applc | |
C (HCQ 4wks) | 2 | 10 | 1.000b | − 0.2 (− 0.340–0.008) | G (no med. 12wks) | 1 | 2 | Not applb,c | Not applc | |
B + C (combined) | 3 | 15 | 1.000a | 1.100 (0.156–7.740) | F + G (combined) | 4 | 4 | 0.236a | Not applc |